A Randomized, Placebo-controlled Crossover Study to Assess the Safety of Administering a Second Dose of a COVID-19 mRNA Vaccine in Individuals Who Experienced a Systemic Allergic Reaction to an Initial Dose
Condition: Systemic Allergic Reaction Interventions: Biological: Pfizer-BioNTech COVID-19 Vaccine; Other: Placebo Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Allergy | Allergy & Immunology | COVID-19 | Infectious Diseases | Pfizer | Research | Study | Vaccines